Upregulation of tumor necrosis factor receptor-associated factor 6 correlated with synovitis severity in rheumatoid arthritis

Lang-Jing Zhu, Lie Dai, Dong-Hui Zheng, Ying‐Qian Mo, Xia Ouyang, Xiuning Wei, Jun Shen, Bai-Yu ZhangArthritis 2012 · DOI

TL;DR

This study investigates the role of Tumor Necrosis Factor Receptor-Associated Factor 6 (TRAF6) in Rheumatoid Arthritis (RA), a chronic inflammatory disease causing joint destruction. Researchers found that TRAF6 is significantly upregulated in RA synovium and its expression levels correlate with the severity of inflammation and the presence of immune cells, suggesting TRAF6's involvement in RA pathogenesis and potential as a therapeutic target.

What Problem Does This Paper Address?

Rheumatoid Arthritis (RA) is a debilitating autoimmune disease characterized by chronic inflammation of the synovium (the lining of joints), leading to the destruction of cartilage and bone. While many cell types and signaling pathways are implicated, the precise mechanisms driving this inflammation and subsequent joint damage remain incompletely understood. Specifically, the role of TRAF6, a key signaling adapter molecule involved in inflammatory pathways and osteoclast differentiation (cells responsible for bone resorption), in the context of RA synovium and its correlation with disease severity was not well-established. This paper aims to fill this knowledge gap by examining TRAF6 expression in RA synovium and its relationship with histological and radiological markers of disease activity and joint destruction.

Methods

The researchers employed immunohistochemistry to detect and quantify TRAF6 expression in synovial tissue samples. They compared RA patients (n=44) with control groups: patients with osteoarthritis (OA, n=9) and orthopedic arthropathies (Orth.A, n=7), considered "less inflamed." Serial sections were stained for TRAF6 and various immune cell markers, including CD68 (macrophages), CD3 (T cells), CD20 (B cells), CD38 (plasma cells), CD79a (B lineage cells), and CD34 (endothelial cells). Double immunofluorescence staining was used to co-localize TRAF6 and CD68. Synovitis severity was assessed using a validated histological scoring system, and joint destruction was evaluated using the Sharp score from radiographs. Statistical analyses, including Mann-Whitney U tests, Kruskal-Wallis tests, and Spearman's rank correlation, were used to analyze the data.

Datasets

The study utilized synovial tissue biopsies from 44 RA patients, 9 OA patients, and 7 Orth.A patients. Radiographs of hands and wrists from RA patients were also used for joint damage assessment. No new datasets or benchmarks were introduced.

Key Insights and Ideas

  • TRAF6 is a key player in RA synovium: The study strongly suggests that TRAF6 is not just present but actively involved in the inflammatory processes within the RA joint.
  • Correlation with inflammation, not just presence: The significance lies not just in TRAF6 being present, but in its expression levels directly correlating with the severity of synovitis and the density of various inflammatory cells. This points towards TRAF6 actively contributing to the inflammatory cascade.
  • TRAF6 and macrophages are linked: The strong correlation between TRAF6 and CD68+ cells (macrophages) is particularly noteworthy, given the known role of macrophages in RA pathogenesis and their potential to differentiate into osteoclasts.
  • Potential therapeutic target: The findings position TRAF6 as a promising candidate for future therapeutic interventions aimed at mitigating RA's inflammatory and destructive processes.

Key Results

  • Elevated TRAF6 in RA: Synovial TRAF6 expression was significantly higher in RA patients compared to OA and Orth.A patients (p < 0.0001).
  • TRAF6 and synovitis severity: Synovial TRAF6 expression showed a significant positive correlation with the synovitis score (r = 0.412, p = 0.006) and inflammatory cell infiltration (r = 0.367, p = 0.014).
  • TRAF6 and immune cell infiltration: TRAF6 expression was significantly correlated with the density of various immune cells in the synovium, including CD68+ cells (intimal: r = 0.636, p < 0.0001; subintimal: r = 0.532, p = 0.005), CD3+ cells (r = 0.478, p = 0.004), CD20+ cells (r = 0.313, p = 0.047), CD38+ cells (r = 0.390, p = 0.020), and CD79a+ cells (r = 0.398, p = 0.032).
  • No correlation with joint destruction: Interestingly, synovial TRAF6 expression did not show a significant correlation with joint destruction parameters like the total Sharp score, erosion subscore, or joint space narrowing subscore.
  • Treatment effects: In a small subgroup of patients followed for 12 months, synovial TRAF6 expression decreased along with improvements in disease activity and synovitis score after treatment, suggesting TRAF6 may reflect disease activity.

Limitations and Future Work

The authors acknowledge that a potential limitation is the lack of demonstrated TRAF6 expression directly in mature osteoclasts or their earlier differentiation stages beyond CD68+ cells. Further research using subchondral tissues from arthroplasty is suggested. The small sample size for repetitive biopsies during treatment follow-up limited the power to detect statistically significant changes. Future work should focus on investigating the exact mechanisms by which TRAF6 affects local inflammation and joint destruction, potentially through the use of TRAF6 inhibitors or siRNA silencing.

Summary updated

Abstract

Elevated synovial TRAF6 expression correlated with synovitis severity and CD68+ cell density in RA. It is, therefore, hypothesized that synovial TRAF6 is involved in the pathogenesis of synovial inflammation and osteoclast differentiation in RA.
BibTeX
@inproceedings{zhu2012upregulation,
  author = {Lang-Jing Zhu and Lie Dai and Dong-Hui Zheng and Ying‐Qian Mo and Xia Ouyang and Xiuning Wei and Jun Shen and Bai-Yu Zhang},
  title = {{Upregulation of tumor necrosis factor receptor-associated factor 6 correlated with synovitis severity in rheumatoid arthritis}},
  booktitle = {Arthritis},
  year = {2012},
  doi = {10.1186/ar3866},
}
Figure